Correlation between ABO blood types and ovarian cancer
Objective To evaluate the relationships of ABO blood types with ovarian cancer onset,International Federation of Gynecology and Obstetrics(FIGO)staging,pathological types.Methods The relevant clinical data of 285 patients with ovarian cancer who underwent initial surgery and were pathologically diagnosed at.Second Hospital,Shaanxi University of Traditional Chinese Medicine were enrolled,including age,menopausal status,presence of malignant ascites,FIGO staging,pathological types,serum carcinoembryonic antigen carcinoembryonic antigen(CA)125,and blood types.Three hundred patients with benign ovarian tumors during the same period were selected as the controls.The relationships of ABO blood types with ovarian cancer onset risk,FIGO staging,and pathological types were retrospectively analyzed.Kolmogorov Smirnov test,F test,x2 test,and Fisher exact probability were used.Results Among the 285 patients with ovarian cancer,there were 83 cases(29.1％)of blood type A,95 cases(33.3％)of type B,72 cases(25.3％)of type O,and 35 cases(12.3％)of type AB.Among the 300 patients with benign ovarian tumors,there were 77 cases(25.7％)blood type A,90 cases(30.0％)of type B,99 cases(33.0％)of type O,and 34 cases(11.3％)of type AB.Type O accounted the highest proportion in the patients with benign ovarian tumors,and type B in the patients with ovarian cancer.There were no statistical differences in age,FIGO staging,pathological types,menopausal status,and CA125 level between the patients of different blood types(all P＞0.05).The logistic regression model showed that blood type B was a risk factor for ovarian cancer in the patients(OR=3.518,95％CI 1.519-8.146,P＜0.05).ABO blood types did not correlate with FIGO staging and pathological type of ovarian cancer(both P＞0.05).Conclusions Blood type B is the most common type in patients with ovarian cancer,and is associated with an increased risk of ovarian cancer.ABO blood types do not correlate with FIGO staging and pathological type of ovarian cancer.
万方数据
维普
